Becton, Dickinson and Company Submits Application to the FDA for a New, At-Home HPV Test

Becton, Dickinson and Company (NYSE:BDX) is one of the top stocks that Grok recommended. On July 31, Becton, Dickinson and Company (NYSE:BDX) announced that it submitted an application to the U.S. FDA for a new, at-home HPV test.

The new HPV test focuses on patients to self-collect a sample at their home using a swab, the size of a Q-tip, simplifying lab processing. According to BD, this method also reports more high-risk strains of HPV compared to other tests on the market today.

A person wearing a state-of-the-art medical device for nerve conduction tests.

“We envision a world where women are empowered with access and a choice for their HPV screening, whether it be in a routine visit at the doctor’s office or the comfort and privacy of their own home via a self-collected sample. Cervical cancer and the loss of more than 4,000 women per year to this devastating disease is preventable, and we believe at-home testing is an important leap forward to our goal of eliminating this type of cancer,”  said Nikos Pavlidis, president of BD Diagnostic Solutions.

BD’s new HPV test will include a state-of-the-art self-collection swab technology that also offers convenient mailing from home to the lab, supporting broader participation in cervical cancer screening programs. The self-collected swab requires no manual sample preparation by clinical laboratory technologists. This process will allow them to focus on higher-value work.

Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company that focuses on the development, manufacturing, and sale of various medical supplies, devices, diagnostic products, and laboratory equipment.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.